(firstQuint)Clinical Trial to Evaluate the Efficacy and Safety of "Immuncell-LC" in the Patients Undergone TACE for Intermediate Stage Hepatocellular Carcinoma.

 ILC-IIT-05 is randomized, open-label, multi-center phase 2 clinical trial.

 To confirm clinical efficacy and safety between 'Immuncell-LC group' and 'non-treatment group', primary outcome, recurrence free survival(RFS) will be evaluated.

 For secondary outcome, overall survival(OS), changes of Alpha Feto Protein(AFP), correlation of between myeloid-derived suppressor cell change and prognosis, adverse event, ECOG-PS and hematological examination will be evaluated.

.

 Clinical Trial to Evaluate the Efficacy and Safety of "Immuncell-LC" in the Patients Undergone TACE for Intermediate Stage Hepatocellular Carcinoma@highlight

To evaluate the efficacy and safety of 'Immuncell-LC group' and 'non-treatment group' in the patients undergone Transarterial Chemoembolization for intermediate stage hepatocellular carcinoma